Infectious Disease Focus: Cidara Cuts 30% Workforce to Prioritize Flu Prevention Therapy
Friday, 13 September 2024, 06:59
Strategic Restructuring in the Face of Infectious Disease
In the current infectious disease landscape, Cidara Therapeutics has made the decisive move to cut 30% of its workforce. This decision stems from a need to prioritize resources for their promising CD388 influenza prevention drug.
Focusing on Clinical Trials
- The company aims to conduct crucial clinical trials for CD388.
- These trials are essential for advancing the drug, targeted specifically towards flu prevention.
- Resources previously allocated to other projects will be redirected.
This realignment reflects Cidara's commitment to addressing pressing infectious disease challenges and signals confidence in CD388's potential impact.
This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.